"By Megan Brooks
Medscape Medical News
The World Health Organization (WHO) has approved the first rapid test for Ebola virus disease for use in hard-hit countries.
The ReEBOV Antigen Rapid Test Kit (Corgenix M"...
The following serious and otherwise important adverse reactions are discussed in greater detail in the WARNINGS AND PRECAUTIONS section of the label:
- Tendinopathy and Tendon Rupture [see WARNINGS AND PRECAUTIONS]
- Exacerbation of Myasthenia Gravis [see WARNINGS AND PRECAUTIONS]
- QT Prolongation [see WARNINGS AND PRECAUTIONS]
- Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
- Other Serious and Sometimes Fatal Reactions [see WARNINGS AND PRECAUTIONS]
- Central Nervous System Effects [see WARNINGS AND PRECAUTIONS]
- Clostridium Difficile-Associated Diarrhea [see WARNINGS AND PRECAUTIONS]
- Peripheral Neuropathy that may be irreversible [see WARNINGS AND PRECAUTIONS]
- Blood Glucose Disturbances [see WARNINGS AND PRECAUTIONS]
- Photosensitivity/Phototoxicity [see WARNINGS AND PRECAUTIONS]
- Development of Drug Resistant Bacteria [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to AVELOX in 14981 patients in 71 active controlled Phase II–IV clinical trials in different indications [see INDICATIONS AND USAGE]. The population studied had a mean age of 50 years (approximately 73% of the population was less than 65 years of age), 50% were male, 63% were Caucasian, 12% were Asian and 9% were Black. Patients received AVELOX 400 mg once daily oral, intravenous, or sequentially (intravenous followed by oral). Treatment duration was usually 6 to 10 days, and the mean number of days on therapy was 9 days.
Discontinuation of AVELOX due to adverse reactions occurred in 5% of patients overall, 4% of patients treated with 400 mg PO, 4% with 400 mg intravenous and 8% with sequential therapy 400 mg oral/intravenous. The most common adverse reactions ( > 0.3%) leading to discontinuation with the 400 mg oral doses were nausea, diarrhea, dizziness, and vomiting. The most common adverse reaction leading to discontinuation with the 400 mg intravenous dose was rash. The most common adverse reactions leading to discontinuation with the 400 mg intravenous/oral sequential dose were diarrhea, pyrexia.
Adverse reactions occurring in 1% of AVELOX-treated patients and less common adverse reactions, occurring in 0.1 to 1% of AVELOX-treated patients, are shown in Tables 2 and Table 3, respectively. The most common adverse drug reactions (3%) are nausea, diarrhea, headache, and dizziness.
Table 2: Common (1% or more) Adverse Reactions
Reported in Active-Controlled Clinical Trials with AVELOX
|System Organ Class||Adverse Reactions||%
|Blood and Lymphatic System Disorders||Anemia||1|
|General Disorders and Administration Site Conditions||Pyrexia||1|
|Investigations||Alanine aminotransferase increased||1|
|Metabolism and Nutritional Disorder||Hypokalemia||1|
|Nervous System Disorders||Headache||4|
Table 3: Less Common (0.1 to less than 1%) Adverse
Reactions Reported in Active-Controlled Clinical Trials with AVELOX (N=14,981)
|System Organ Class||Adverse Reactions|
|Blood and Lymphatic System Disorders||Thrombocythemia|
|Cardiac Disorders||Atrial fibrillation|
|System Organ Class||Adverse Reactions|
|Ear and Labyrinth Disorders||Vertigo|
|Eye Disorders||Vision blurred|
|Gastrointestinal Disorders||Dry mouth|
|Gastroesophageal reflux disease|
|General Disorders and Administration Site Conditions||Fatigue|
|Infusion site extravasation|
|Hepatobiliary disorders||Hepatic function abnormal|
|Infections and Infestations||Candidiasis|
|Investigations||Aspartate aminotransferase increased|
|Blood alkaline phosphatase increased|
|Electrocardiogram QT prolonged|
|Blood lactate dehydrogenase increased|
|Blood amylase increased|
|Blood creatinine increased|
|Blood urea increased|
|Prothrombin time prolonged|
|Eosinophil count increased|
|Activated partial thromboplastin time prolonged|
|Blood triglycerides increased|
|Blood uric acid increased|
|Metabolism and Nutrition Disorders||Hyperglycemia|
|Musculoskeletal and Connective Tissue Disorders||Back pain|
|Pain in extremity|
|Nervous System Disorders||Dysgeusia|
|System Organ Class||Adverse Reactions|
|Renal and Urinary Disorders||Renal failure|
|Reproductive System and Breast Disorders||Vulvovaginal pruritus|
|Respiratory, Thoracic, and Mediastinal Disorders||Dyspnea|
|Skin and Subcutaneous Tissue Disorders||Rash|
Changes in laboratory parameters, which are not listed above and which occurred in 2% or more of patients and at an incidence greater than in controls included: increases in mean corpuscular hemoglobin (MCH), neutrophils, white blood cells (WBCs), prothrombin time (PT) ratio, ionized calcium, chloride, albumin, globulin, bilirubin; decreases in hemoglobin, red blood cells (RBCs), neutrophils, eosinophils, basophils, glucose, oxygen partial pressure (pO2), bilirubin, and amylase. It cannot be determined if any of the above laboratory abnormalities were caused by the drug or the underlying condition being treated.
Table 4 below lists adverse reactions that have been identified during post-approval use of AVELOX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Table 4: Postmarketing Reports of Adverse Drug
|System Organ Class||Adverse Reaction|
|Blood and Lymphatic System Disorders||Agranulocytosis|
|Pancytopenia [see WARNINGS AND PRECAUTIONS]|
|Cardiac Disorders||Ventricular tachyarrhythmias (including in very rare cases cardiac arrest and torsade de pointes, and usually in patients with concurrent severe underlying proarrhythmic conditions)|
|Ear and Labyrinth Disorders||Hearing impairment, including deafness (reversible in majority of cases)|
|Eye Disorders||Vision loss (especially in the course of CNS reactions, transient in majority of cases)|
|Hepatobiliary Disorders||Hepatitis (predominantly cholestatic)|
|Hepatic failure (including fatal cases)|
|Acute hepatic necrosis [see WARNINGS AND PRECAUTIONS]|
|Immune System Disorders||Anaphylactic reaction|
|Angioedema (including laryngeal edema) [see WARNINGS AND PRECAUTIONS]|
|Musculoskeletal and Connective Tissue Disorders||Tendon rupture [seeWARNINGS AND PRECAUTIONS]|
|Nervous System Disorders||Altered coordination|
|Abnormal gait [see WARNINGS AND PRECAUTIONS]|
|Myasthenia gravis (exacerbation of) [see WARNINGS AND PRECAUTIONS]|
|Peripheral neuropathy (that may be irreversible), polyneuropathy [see WARNINGS AND PRECAUTIONS]|
|Psychiatric Disorders||Psychotic reaction (very rarely culminating in self-injurious behavior, such as suicidal ideation/thoughts or suicide attempts [see WARNINGS AND PRECAUTIONS]|
|Renal and Urinary Disorders||Interstitial nephritis [see WARNINGS AND PRECAUTIONS]|
|Respiratory, Thoracic and Mediastinal Disorders||Allergic pneumonitis [see WARNINGS AND PRECAUTIONS]|
|Skin and Subcutaneous Tissue Disorders||Photosensitivity/phototoxicity reaction [see WARNINGS AND PRECAUTIONS]|
|Toxic epidermal necrolysis [see WARNINGS AND PRECAUTIONS]|
Read the Avelox (moxifloxacin hcl) Side Effects Center for a complete guide to possible side effects
Antacids, Sucralfate, Multivitamins And Other Products Containing Multivalent Cations
Fluoroquinolones, including AVELOX, form chelates with alkaline earth and transition metal cations. Oral administration of AVELOX with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of AVELOX, resulting in systemic concentrations considerably lower than desired. Therefore, AVELOX should be taken at least 4 hours before or 8 hours after these agents. [See DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY]
Fluoroquinolones, including AVELOX, have been reported to enhance the anticoagulant effects of warfarin or its derivatives in the patient population. In addition, infectious disease and its accompanying inflammatory process, age, and general status of the patient are risk factors for increased anticoagulant activity. Therefore the prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if AVELOX is administered concomitantly with warfarin or its derivatives. [See ADVERSE REACTIONS and CLINICAL PHARMACOLOGY]
Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with fluoroquinolones, including AVELOX, and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered. If a hypoglycemic reaction occurs, AVELOX should be discontinued and appropriate therapy should be initiated immediately. [See WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
Nonsteroidal Anti-Inflammatory Drugs
The concomitant administration of a nonsteroidal anti-inflammatory drug (NSAID) with a fluoroquinolone, including AVELOX, may increase the risks of CNS stimulation and convulsions [see WARNINGS AND PRECAUTIONS].
Drugs That Prolong QT
There is limited information available on the potential for a pharmacodynamic interaction in humans between AVELOX and other drugs that prolong the QTc interval of the electrocardiogram. Sotalol, a Class III antiarrhythmic, has been shown to further increase the QTc interval when combined with high doses of intravenous AVELOX in dogs. Therefore, AVELOX should be avoided with Class IA and Class III antiarrhythmics. [See WARNINGS AND PRECAUTIONS and Nonclinical Toxicology.]
Read the Avelox Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 9/2/2015
Additional Avelox Information
Avelox - User Reviews
Avelox User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.